ReleaseWire Connect

According to a new series of reports on the Mexico market for minimally invasive spinal (MIS) implants by iData Research (www.idataresearch.com), the country imports minimally invasive devices, mostly from American and European manufacturers. However, the U.S. dollar has seen strong growth recently. As a result, it has been less profitable for companies to import MIS devices and this has stunted market growth.

According to a new series of reports on the U.S. market for immunology drugs by iData Research (www.idataresearch.com), projections show a gradual fall in HUMIRA® market share after 2020 due to the entry of infliximab and etanercept biosimilars, as well as other new drugs. The revenues from HUMIRA® currently account for an estimated 34% of the total U.S. immunology drug market. However, since the patent expiry for HUMIRA® in 2016, there are currently two HUMIRA® biosimilars, namely Amjevita™ and Cyltezo™. However, these drugs are not able to launch due to Humira's strong ancillary patents which will protect them from losing their exclusivity until 2023. These products will cause the average selling price (ASP) of HUMIRA® to decline over the next several years, further deepening the market share erosion caused by biosimilars after 2023.

According to a new series of reports on the U.S. market for dental prosthetics by iData Research (www.idataresearch.com), an ongoing trend driving market value is the increasing movement towards digitization in the dentures segment due to their relatively high average selling prices. The digital denture market encompasses both dentures that are produced via 3D printers and those developed from CAD/CAM technology. The rapid increases in metal prices, particularly gold, is also contributing to notable positive growth in the market. On the other hand, declines in the costly veneer market will slow total dental prosthetic market growth.

According to a new exciting and unprecedented 1000+ page report series on the U.S. market for immunology drugs by iData Research (www.idataresearch.com), the immunology market is facing strong competition and cost pressure from new entrants, which limits the commercial potential of these drugs. Another concern is the significant unmet needs to treat relevant diseases, in terms of safer treatments and more convenient administration.

According to a new series of reports on the European market for minimally invasive surgery (MIS) spinal implants by iData Research (www.idataresearch.com), the number of MIS interbody procedures performed in Europe approached 20,000 in 2016. This includes minimally invasive transforaminal lumbar interbody fusion (MITLIF), minimally invasive posterior lumbar interbody fusion (MIPLIF), lateral lumbar interbody fusion (LLIF), and oblique lumbar interbody fusion (OLIF), including NuVasive's popular XLIF® procedure.

According to a new series of reports on the U.S. market for orthopedic small bone and joint devices by iData Research (www.idataresearch.com), elbow open reduction internal fixation (ORIF) is growing due to the use of anatomic plates which are low profile designed specifically for the olecranon, coronoid and distal humerus. The fastest growing procedure of the elbow is complete replacement which is prescribed in cases of arthritis, fractures which cannot be managed using other techniques and for revision of the elbow. The elbow repair market is segmented by primary elbow and radial head implants with a combined market value in the U.S. of just under $50 million in 2016.

According to a new series of reports on the U.S. market for laparoscopic devices by iData Research (www.idataresearch.com), disposable instruments are preferred over reusable instruments within the United States, but reposable devices, which have a reusable component and a disposable component, are becoming more popular. Ongoing research continues to drive technological advancements, and newer, multifunctional devices that can play a variety of roles during laparoscopic surgery continue to be favored.

According to a new series of reports on the European market for infusion therapy devices by iData Research (www.idataresearch.com), the total market for intravenous (IV) sets is expected to maintain moderate growth over the next several years. This trend will be solely driven by continued growth in unit sales as the average selling price (ASP) of all device types has been decreasing due to fierce competition and sluggish economic conditions. This market includes primary (dedicated and non-dedicated) IV sets, secondary IV sets and IV extension sets.

According to a new series of reports on the European market for vertebral compression fracture (VCF) devices by iData Research (www.idataresearch.com), percutaneous vertebral augmentation (PVA) devices comprised the vast majority of the market. This represents a disproportionate share of the market compared to the procedure volumes, a result of the higher cost of PVA procedures. However, due to expected price declines, the PVA segment is forecast to experience higher procedural growth rates compared to vertebroplasty, further increasing its share of the overall VCF device market.

According to a new series of reports on the U.S. market for orthopedic soft tissue repair and sports medicine by iData Research (www.idataresearch.com), the number of shoulder labrum procedures has been growing quickly as a result of the popularization of this technique and the rise of all-suture anchors. However, surgeons are finding that shoulder labrum repair is not as effective at treating bicep pain as previously thought. As a result, shoulder labrum repair procedure growth should slow in the following years.